Oncolytic virotherapy for cancer: biological mechanisms, clinical advances, and future perspectives.

Συγγραφείς: Halawa EM; Department of Botany and Microbiology, Faculty of Science, Cairo University, Giza, 12613, Egypt. esraahalawa@gstd.sci.cu.edu.eg., AbdelHamid SG; Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, Egypt., ElHefnawi M; Biomedical Informatics and Chemoinformatics Group, Informatics and Systems Department, National Research Centre, Tahrir Street, Cairo, 12311, Egypt. Mahef111@gmail.com.

Πηγή: Clinical and experimental medicine [Clin Exp Med] 2026 Oct 16; Vol. 26 (1). Date of Electronic Publication: 2026 Oct 16.

Τύπος έκδοσης: Journal Article; Review

Στοιχεία περιοδικού: Publisher: Springer-Verlag Italia Country of Publication: Italy NLM ID: 100973405 Publication Model: Electronic Cited Medium: Internet ISSN: 1591-9528 (Electronic) Linking ISSN: 15918890 NLM ISO Abbreviation: Clin Exp Med Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Oncolytic Virotherapy*/methods , Oncolytic Virotherapy*/trends , Neoplasms*/therapy , Neoplasms*/immunology , Oncolytic Viruses*/genetics , Oncolytic Viruses*/physiology, Immunotherapy/methods ; Humans ; Animals ; Tumor Microenvironment

Stacked Waves and Qualitative Analysis of an Oncolytic Virus-Immune Model.

Συγγραφείς: Mohammadnejad N; Department of Mathematical and Statistical Sciences, University of Alberta, T6G 2R3, Edmonton, AB, Canada., Hillen T; Department of Mathematical and Statistical Sciences, University of Alberta, T6G 2R3, Edmonton, AB, Canada. thillen@ualberta.ca.

Πηγή: Bulletin of mathematical biology [Bull Math Biol] 2026 Oct 03; Vol. 88 (11). Date of Electronic Publication: 2026 Oct 03.

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: Springer Country of Publication: United States NLM ID: 0401404 Publication Model: Electronic Cited Medium: Internet ISSN: 1522-9602 (Electronic) Linking ISSN: 00928240 NLM ISO Abbreviation: Bull Math Biol Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Oncolytic Virotherapy*/statistics & numerical data , Oncolytic Virotherapy*/methods , Oncolytic Viruses*/immunology , Oncolytic Viruses*/physiology , Neoplasms*/therapy , Neoplasms*/immunology , Neoplasms*/pathology , Models, Immunological*, Mathematical Concepts ; Humans ; Computer Simulation ; Animals ; Models, Biological

Allee Effect and Oncolytic Virotherapy: Different Therapeutic Outcomes for Different Tumour Growth.

Συγγραφείς: Chen J; Department of Mathematics, Swinburne University of Technology, John Street, Hawthorn, VIC, 3122, Australia., Frascoli F; Department of Mathematics, Swinburne University of Technology, John Street, Hawthorn, VIC, 3122, Australia. ffrascoli@swin.edu.au., Zhang T; Department of Mathematics, Swinburne University of Technology, John Street, Hawthorn, VIC, 3122, Australia. tonghuazhang@swin.edu.au.

Πηγή: Bulletin of mathematical biology [Bull Math Biol] 2026 Sep 02; Vol. 88 (10). Date of Electronic Publication: 2026 Sep 02.

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: Springer Country of Publication: United States NLM ID: 0401404 Publication Model: Electronic Cited Medium: Internet ISSN: 1522-9602 (Electronic) Linking ISSN: 00928240 NLM ISO Abbreviation: Bull Math Biol Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Oncolytic Virotherapy*/statistics & numerical data , Oncolytic Virotherapy*/methods , Neoplasms*/therapy , Neoplasms*/pathology , Neoplasms*/virology , Models, Biological*, Neoplasm Recurrence, Local/pathology ; Neoplasm Recurrence, Local/prevention & control ; Humans ; Mathematical Concepts ; Treatment Outcome ; Tumor Burden ; Animals ; Computer Simulation ; Logistic Models ; Oncolytic Viruses

Integration of a multimeric STAT consensus site into the adenoviral genome to interfere with IFN signaling represents a novel concept to improve oncolytic virotherapy.

Συγγραφείς: Wang D; Department of Urology, TUM Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany., Nassua S; Department of Urology, TUM Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany., Mantwill K; Department of Urology, TUM Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany., Zhao Y; Department of Urology, TUM Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany., Bambach JC; Department of Urology, TUM Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany., Gschwend JE; Department of Urology, TUM Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany., Holm PS; Department of Urology, TUM Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.; Department of Oral and Maxillofacial Surgery, Innsbruck Medical University, Innsbruck, Austria., Nawroth R; Department of Urology, TUM Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.

Πηγή: Journal of virology [J Virol] 2026 Sep 22; Vol. 100 (9), pp. e0106826. Date of Electronic Publication: 2026 Aug 10.

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: American Society For Microbiology Country of Publication: United States NLM ID: 0113724 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-5514 (Electronic) Linking ISSN: 0022538X NLM ISO Abbreviation: J Virol Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Oncolytic Virotherapy*/methods , Interferons*/metabolism , Oncolytic Viruses*/genetics , STAT Transcription Factors*/genetics , STAT Transcription Factors*/metabolism , Adenoviridae*/genetics , Adenoviridae*/physiology , Genome, Viral*, Adenovirus E1A Proteins/genetics ; Adenovirus E1A Proteins/metabolism ; Janus Kinases/metabolism ; Humans ; Signal Transduction ; Virus Replication ; Cell Line, Tumor

Whole-Transcriptome Profiling of Murine GL261 Glioma Reveals Signatures Consistent with Distinct Immune Reprogramming Induced by Oncolytic Virotherapy with VV-GMCSF-Lact and Anti-PD-1 Therapy.

Συγγραφείς: Chesnokova AS; Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Lavrentyev Avenue 8, Novosibirsk 630090, Russia., Ageenko AB; Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Lavrentyev Avenue 8, Novosibirsk 630090, Russia.; Research Center for Genetics and Life Sciences, Sirius University of Science and Technology, Krasnodar Region, Sirius (Federal Territory of Sirius), Sochi 354340, Russia., Vasileva NS; Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Lavrentyev Avenue 8, Novosibirsk 630090, Russia.; Research Center for Genetics and Life Sciences, Sirius University of Science and Technology, Krasnodar Region, Sirius (Federal Territory of Sirius), Sochi 354340, Russia., Byvakina AA; Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Lavrentyev Avenue 8, Novosibirsk 630090, Russia., Nushtaeva AA; Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Lavrentyev Avenue 8, Novosibirsk 630090, Russia.; Research Center for Genetics and Life Sciences, Sirius University of Science and Technology, Krasnodar Region, Sirius (Federal Territory of Sirius), Sochi 354340, Russia., Leonteva AA; Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Lavrentyev Avenue 8, Novosibirsk 630090, Russia.; Research Center for Genetics and Life Sciences, Sirius University of Science and Technology, Krasnodar Region, Sirius (Federal Territory of Sirius), Sochi 354340, Russia., Savinovskaya YI; Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Lavrentyev Avenue 8, Novosibirsk 630090, Russia., Kochneva GV; State Research Center of Virology and Biotechnology 'Vector', Rospotrebnadzor, Koltsovo 630559, Russia., Richter VA; Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Lavrentyev Avenue 8, Novosibirsk 630090, Russia., Kuligina EV; Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Lavrentyev Avenue 8, Novosibirsk 630090, Russia.; Oncostar LLC, Inzhenernaya Street 23, Novosibirsk 630090, Russia., Semenov DV; Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Lavrentyev Avenue 8, Novosibirsk 630090, Russia.

Πηγή: International journal of molecular sciences [Int J Mol Sci] 2026 Sep 11; Vol. 27 (18). Date of Electronic Publication: 2026 Sep 11.

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Glioma*/genetics , Glioma*/therapy , Glioma*/immunology , Oncolytic Virotherapy*/methods , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Granulocyte-Macrophage Colony-Stimulating Factor*/genetics , Immune Checkpoint Inhibitors*/pharmacology , Brain Neoplasms*/genetics , Brain Neoplasms*/therapy , Brain Neoplasms*/immunology , Transcriptome*, Immunotherapy/methods ; Animals ; Mice ; Gene Expression Profiling ; Mice, Inbred C57BL ; Cell Line, Tumor ; Gene Expression Regulation, Neoplastic ; Signal Transduction

Anti-cancer efficacy of combined vaccine-strain measles and mumps viruses against colorectal cancer: an experimental study.

Συγγραφείς: Hung TX; Department of Gastrointestinal Endoscopy, 108 Military Central Hospital; 1st Tran Hung Dao Street, Hai Ba Trung Ward, Hanoi City, Vietnam., Tung ND; Department of Quality Management, 108 Military Central Hospital; 1st Tran Hung Dao Street, Hai Ba Trung Ward, Hanoi City, Vietnam., Huong NT; Department of Hepatobiliary, 108 Military Central Hospital, 1st Tran Hung Dao Street, Hai Ba Trung Ward, Hanoi City, Vietnam., Hoa DT; Department of Experimental Medicine, 108 Military Central Hospital; 1st Tran Hung Dao Street, Hai Ba Trung Ward, Hanoi City, Vietnam., Cuong LD; Department of Experimental Medicine, 108 Military Central Hospital; 1st Tran Hung Dao Street, Hai Ba Trung Ward, Hanoi City, Vietnam. leduycuong76@gmail.com.

Πηγή: Molecular biology reports [Mol Biol Rep] 2026 Sep 05; Vol. 53 (1). Date of Electronic Publication: 2026 Sep 05.

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: Reidel Country of Publication: Netherlands NLM ID: 0403234 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-4978 (Electronic) Linking ISSN: 03014851 NLM ISO Abbreviation: Mol Biol Rep Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Colorectal Neoplasms*/therapy , Colorectal Neoplasms*/virology , Measles virus*/immunology , Mumps virus*/immunology , Oncolytic Virotherapy*/methods, Animals ; Humans ; Mice ; Mice, Nude ; Xenograft Model Antitumor Assays ; Apoptosis ; HT29 Cells ; Cell Survival ; Cell Line, Tumor ; Oncolytic Viruses ; Mice, Inbred BALB C

Emerging and Re-Emerging Viral Pathogens in Oncolytic Virotherapy: A Comprehensive Review.

Συγγραφείς: An X; The VIP Department, School and Hospital of Stomatology, China Medical University, Liaoning Provincial Key Laboratory of Oral Diseases, Shenyang, China., Liu N; Department of Pathology, the First Affiliated Hospital and College of Basic Medical Sciences of China Medical University, Shenyang, China., Liu J; Department of Periodontics, School and Hospital of Stomatology, China Medical University, Liaoning Provincial Key Laboratory of Oral Diseases, Shenyang, China.

Πηγή: Reviews in medical virology [Rev Med Virol] 2026 Sep; Vol. 36 (5), pp. e70167.

Τύπος έκδοσης: Journal Article; Review

Στοιχεία περιοδικού: Publisher: Wiley Country of Publication: England NLM ID: 9112448 Publication Model: Print Cited Medium: Internet ISSN: 1099-1654 (Electronic) Linking ISSN: 10529276 NLM ISO Abbreviation: Rev Med Virol Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Oncolytic Virotherapy*/methods , Oncolytic Viruses*/genetics , Oncolytic Viruses*/physiology , Neoplasms*/therapy , Neoplasms*/virology, SARS-CoV-2/genetics ; SARS-CoV-2/pathogenicity ; Zika Virus/genetics ; Zika Virus/pathogenicity ; West Nile virus/genetics ; Dengue Virus/genetics ; Dengue Virus/pathogenicity ; Humans ; Animals

Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy.

Συγγραφείς: Jove M; Medical Oncology Department, Institut Catala d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain., Braña I; Vall d´Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Oliva M; Medical Oncology Department, Institut Catala d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain., Hernando-Calvo A; Vall d´Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Erasun C; Medical Oncology Department, Institut Catala d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain., Mato-Berciano A; Theriva Biologics SL, Parets del Vallès, Barcelona, Spain., Maliandi MV; Theriva Biologics SL, Parets del Vallès, Barcelona, Spain., Torres-Manjon S; Cancer Immunotherapy Group, Oncobell and ProCure programs, IDIBELL-Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain., Rojas LA; Theriva Biologics SL, Parets del Vallès, Barcelona, Spain., Connelly S; Theriva Biologics Inc, Rockville, Maryland., Bazan-Peregrino M; Theriva Biologics SL, Parets del Vallès, Barcelona, Spain., Moreno R; Cancer Immunotherapy Group, Oncobell and ProCure programs, IDIBELL-Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain., Martínez de Villarreal J; Epithelial Carcinogenesis Group, Spanish National Cancer Research Center-CNIO, Madrid, Spain.; CIBERONC, Madrid, Spain., Real FX; Epithelial Carcinogenesis Group, Spanish National Cancer Research Center-CNIO, Madrid, Spain.; CIBERONC, Madrid, Spain.; Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain., Le C; Theriva Biologics Inc, Rockville, Maryland., Nuciforo P; Molecular Oncology Group, VHIO, Barcelona, Spain., Alemany R; Theriva Biologics SL, Parets del Vallès, Barcelona, Spain.; Cancer Immunotherapy Group, Oncobell and ProCure programs, IDIBELL-Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain., Capellà G; CIBERONC, Madrid, Spain.; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL-ONCOBELL, Hospitalet de Llobregat, Barcelona, Spain., Blasco C; Theriva Biologics SL, Parets del Vallès, Barcelona, Spain., Cascalló M; Theriva Biologics SL, Parets del Vallès, Barcelona, Spain., Mesía R; Medical Oncology Department, Institut Catala d'Oncologia, Badalona, B-ARGO group, CARE program, IGTP, Badalona, Spain.

Πηγή: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2026 Sep 01; Vol. 32 (17), pp. 3786-3798.

Τύπος έκδοσης: Journal Article; Clinical Trial, Phase I

Στοιχεία περιοδικού: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Antibodies, Monoclonal*/administration & dosage , Antibodies, Monoclonal*/adverse effects , Adenoviridae*/genetics , Oncolytic Virotherapy*/methods , Oncolytic Virotherapy*/adverse effects , Squamous Cell Carcinoma of Head and Neck*/therapy , Squamous Cell Carcinoma of Head and Neck*/pathology , Squamous Cell Carcinoma of Head and Neck*/immunology , Oncolytic Viruses*/genetics , Head and Neck Neoplasms*/therapy , Head and Neck Neoplasms*/pathology , Head and Neck Neoplasms*/immunology, Immunotherapy/methods ; Antineoplastic Agents, Immunological/administration & dosage ; Humans ; Female ; Male ; Middle Aged ; Aged ; Combined Modality Therapy ; Adult

Treatment sequence of stem cell delivered heterologous oncolytic virus impact on tumor microenvironment in immunocompetent ovarian cancer model.

Συγγραφείς: Abd El-Fattah EE; Department of Stem Cell Biology and Regenerative Medicine, Beckman Research Institute of City of Hope, Duarte, CA, United States., Flores L; Department of Stem Cell Biology and Regenerative Medicine, Beckman Research Institute of City of Hope, Duarte, CA, United States., Lara J; Department of Stem Cell Biology and Regenerative Medicine, Beckman Research Institute of City of Hope, Duarte, CA, United States., Ngai G; Department of Stem Cell Biology and Regenerative Medicine, Beckman Research Institute of City of Hope, Duarte, CA, United States., Mooney R; Department of Stem Cell Biology and Regenerative Medicine, Beckman Research Institute of City of Hope, Duarte, CA, United States., Aboody K; Department of Stem Cell Biology and Regenerative Medicine, Beckman Research Institute of City of Hope, Duarte, CA, United States.

Πηγή: Frontiers in immunology [Front Immunol] 2026 Aug 31; Vol. 17, pp. 1898617. Date of Electronic Publication: 2026 Aug 31 (Print Publication: 2026).

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Ovarian Neoplasms*/therapy , Ovarian Neoplasms*/immunology , Ovarian Neoplasms*/pathology , Oncolytic Virotherapy*/methods , Tumor Microenvironment*/immunology , Oncolytic Viruses*/genetics , Oncolytic Viruses*/immunology , Mesenchymal Stem Cells*, Vaccinia virus/genetics ; Adenoviridae/genetics ; Dendritic Cells/immunology ; Female ; Animals ; Mice ; Humans ; Mice, Inbred C57BL ; Disease Models, Animal ; Cell Line, Tumor ; Immunocompetence

Oncolytic viruses in head and neck cancer: therapeutic promise and translational challenges.

Συγγραφείς: Wang H; Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.; Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, Shandong, China.; Shandong Provincial Key Laboratory of Neuroimmune Interaction and Regulation, Yantai, Shandong, China.; Yantai Key Laboratory of Otorhinolaryngologic Diseases, Yantai, Shandong, China., Shen H; Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.; Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, Shandong, China.; Shandong Provincial Key Laboratory of Neuroimmune Interaction and Regulation, Yantai, Shandong, China.; Yantai Key Laboratory of Otorhinolaryngologic Diseases, Yantai, Shandong, China., Zhang M; Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.; Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, Shandong, China.; Shandong Provincial Key Laboratory of Neuroimmune Interaction and Regulation, Yantai, Shandong, China.; Yantai Key Laboratory of Otorhinolaryngologic Diseases, Yantai, Shandong, China., Mou Y; Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.; Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, Shandong, China.; Shandong Provincial Key Laboratory of Neuroimmune Interaction and Regulation, Yantai, Shandong, China.; Yantai Key Laboratory of Otorhinolaryngologic Diseases, Yantai, Shandong, China., Ren C; Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.; Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, Shandong, China.; Shandong Provincial Key Laboratory of Neuroimmune Interaction and Regulation, Yantai, Shandong, China.; Yantai Key Laboratory of Otorhinolaryngologic Diseases, Yantai, Shandong, China., Sun Y; Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.; Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, Shandong, China.; Shandong Provincial Key Laboratory of Neuroimmune Interaction and Regulation, Yantai, Shandong, China.; Yantai Key Laboratory of Otorhinolaryngologic Diseases, Yantai, Shandong, China., Liu W; Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.; Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, Shandong, China.; Shandong Provincial Key Laboratory of Neuroimmune Interaction and Regulation, Yantai, Shandong, China.; Yantai Key Laboratory of Otorhinolaryngologic Diseases, Yantai, Shandong, China., Sun C; Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.; Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, Shandong, China.; Shandong Provincial Key Laboratory of Neuroimmune Interaction and Regulation, Yantai, Shandong, China.; Yantai Key Laboratory of Otorhinolaryngologic Diseases, Yantai, Shandong, China., Li D; Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.; Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, Shandong, China.; Shandong Provincial Key Laboratory of Neuroimmune Interaction and Regulation, Yantai, Shandong, China.; Yantai Key Laboratory of Otorhinolaryngologic Diseases, Yantai, Shandong, China., Li Y; Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.; Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, Shandong, China.; Shandong Provincial Key Laboratory of Neuroimmune Interaction and Regulation, Yantai, Shandong, China.; Yantai Key Laboratory of Otorhinolaryngologic Diseases, Yantai, Shandong, China., Qu P; Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.; Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, Shandong, China.; Shandong Provincial Key Laboratory of Neuroimmune Interaction and Regulation, Yantai, Shandong, China.; Yantai Key Laboratory of Otorhinolaryngologic Diseases, Yantai, Shandong, China., Song X; Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.; Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, Shandong, China.; Shandong Provincial Key Laboratory of Neuroimmune Interaction and Regulation, Yantai, Shandong, China.; Yantai Key Laboratory of Otorhinolaryngologic Diseases, Yantai, Shandong, China.

Πηγή: Frontiers in immunology [Front Immunol] 2026 Aug 28; Vol. 17, pp. 1889008. Date of Electronic Publication: 2026 Aug 28 (Print Publication: 2026).

Τύπος έκδοσης: Journal Article; Review

Στοιχεία περιοδικού: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Oncolytic Virotherapy*/methods , Oncolytic Viruses*/genetics , Oncolytic Viruses*/immunology , Head and Neck Neoplasms*/therapy , Head and Neck Neoplasms*/immunology , Squamous Cell Carcinoma of Head and Neck*/therapy , Squamous Cell Carcinoma of Head and Neck*/immunology, Tumor Microenvironment/immunology ; Humans ; Animals ; Translational Research, Biomedical

Systematic review and multilevel meta-analysis of preclinical survival outcomes of Zika virus-based oncolytic therapy in glioblastoma.

Συγγραφείς: Caribé Sena A; Faculdade ZARNS, Salvador, Bahia, Brazil. arthurcaribe.17@hotmail.com., Santana MI; Faculdade ZARNS, Salvador, Bahia, Brazil., Pinto Costa Rocha V; Instituto de Tecnologias em Saúde, Universidade SENAI CIMATEC, Salvador, Bahia, Brazil., Miranda de Avellar L; Serviço de Neurocirurgia, Hospital Geral Roberto Santos, Salvador, Bahia, Brazil.

Πηγή: Journal of neurovirology [J Neurovirol] 2026 Aug 27; Vol. 32 (5). Date of Electronic Publication: 2026 Aug 27.

Τύπος έκδοσης: Journal Article; Meta-Analysis; Systematic Review

Στοιχεία περιοδικού: Publisher: Springer Country of Publication: United States NLM ID: 9508123 Publication Model: Electronic Cited Medium: Internet ISSN: 1538-2443 (Electronic) Linking ISSN: 13550284 NLM ISO Abbreviation: J Neurovirol Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Brain Neoplasms*/immunology , Brain Neoplasms*/mortality , Brain Neoplasms*/pathology , Brain Neoplasms*/therapy , Glioblastoma*/immunology , Glioblastoma*/mortality , Glioblastoma*/pathology , Glioblastoma*/therapy , Oncolytic Virotherapy*/methods , Oncolytic Viruses*/genetics , Oncolytic Viruses*/immunology , Oncolytic Viruses*/physiology , Zika Virus*/physiology , Zika Virus*/immunology , Zika Virus*/genetics, Immune Checkpoint Inhibitors/therapeutic use ; Neoplastic Stem Cells/virology ; Neoplastic Stem Cells/immunology ; Neoplastic Stem Cells/drug effects ; Animals ; Humans

A reaction-diffusion delay model for spatial tumor virotherapy with optimal control.

Συγγραφείς: Rihan FA; Department of Mathematical Sciences, College of Science, UAE University, Al-Ain, 15551, UAE.

Πηγή: Mathematical biosciences and engineering : MBE [Math Biosci Eng] 2026 Aug 18; Vol. 23 (8), pp. 2489-2515.

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: AIMS Press Country of Publication: United States NLM ID: 101197794 Publication Model: Print Cited Medium: Internet ISSN: 1551-0018 (Electronic) Linking ISSN: 15471063 NLM ISO Abbreviation: Math Biosci Eng Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Oncolytic Virotherapy*/methods , Neoplasms*/therapy , Neoplasms*/immunology, T-Lymphocytes, Cytotoxic/immunology ; Humans ; Computer Simulation ; Oncolytic Viruses ; Animals ; Models, Biological ; Diffusion ; Algorithms

Fully intravenous split-dose administration of the oncolytic adenovirus TILT-123 in advanced solid tumors.

Συγγραφείς: Jirovec E; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Jalkanen KJ; Comprehensive Cancer Center, HUS Helsinki University Hospital, Helsinki, Finland., Quixabeira DCA; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; TILT Biotherapeutics Oy, Helsinki, Finland., Clubb JHA; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; TILT Biotherapeutics Oy, Helsinki, Finland., Alanko T; Docrates Cancer Center, Helsinki, Finland., Kudling TV; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; TILT Biotherapeutics Oy, Helsinki, Finland., Arias V; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Pakola SA; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Grönberg-Vähä-Koskela S; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; Comprehensive Cancer Center, HUS Helsinki University Hospital, Helsinki, Finland., van der Heijden M; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Färkkilä A; Research Programs in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Institute for Molecular Medicine Finland, Helsinki Institute Sciences, University of Helsinki, Helsinki, Finland; Clinical Trials Unit, Department of Oncology & Department of Obstetrics and Gynecology, Helsinki University Hospital, Helsinki, Finland., Kononen J; Docrates Cancer Center, Helsinki, Finland., Sormunen J; Docrates Cancer Center, Helsinki, Finland., Kemppainen J; Docrates Cancer Center, Helsinki, Finland; Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, Finland., Hellesuo M; Docrates Cancer Center, Helsinki, Finland., Haybout L; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; TILT Biotherapeutics Oy, Helsinki, Finland., Kistler C; TILT Biotherapeutics Oy, Helsinki, Finland., Sorsa S; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; TILT Biotherapeutics Oy, Helsinki, Finland., Havunen R; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; TILT Biotherapeutics Oy, Helsinki, Finland., Santos JM; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; TILT Biotherapeutics Oy, Helsinki, Finland., Kanerva A; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; Department of Gynecology and Obstetrics, Helsinki University Hospital, Helsinki, Finland., Cervera-Carrascon V; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; TILT Biotherapeutics Oy, Helsinki, Finland., Hemminki O; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; Department of Urology, Helsinki University Hospital, Helsinki, Finland., Hemminki A; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; Comprehensive Cancer Center, HUS Helsinki University Hospital, Helsinki, Finland; TILT Biotherapeutics Oy, Helsinki, Finland. Electronic address: akseli.hemminki@helsinki.fi.

Πηγή: Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2026 Aug 05; Vol. 34 (8), pp. 4670-4686. Date of Electronic Publication: 2026 May 13.

Τύπος έκδοσης: Journal Article; Clinical Trial, Phase I

Στοιχεία περιοδικού: Publisher: Cell Press Country of Publication: United States NLM ID: 100890581 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1525-0024 (Electronic) Linking ISSN: 15250016 NLM ISO Abbreviation: Mol Ther Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Adenoviridae*/genetics , Oncolytic Viruses*/genetics , Neoplasms*/therapy , Neoplasms*/mortality , Neoplasms*/pathology , Neoplasms*/genetics , Oncolytic Virotherapy*/methods , Oncolytic Virotherapy*/adverse effects , Genetic Vectors*/administration & dosage , Genetic Vectors*/genetics, Interleukin-2/genetics ; Tumor Necrosis Factor-alpha/genetics ; Humans ; Female ; Male ; Middle Aged ; Aged ; Treatment Outcome ; Administration, Intravenous ; Positron Emission Tomography Computed Tomography ; Adult

Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.

Συγγραφείς: Tyson MD 2nd; Department of Urology, Mayo Clinic, Phoenix, AZ, USA. Electronic address: tyson.mark@mayo.edu., Nam JK; Department of Urology, Pusan National University Yangsan Hospital, Yangsan, South Korea., Joshi SS; Department of Urology, Emory University School of Medicine, Atlanta, GA, USA., Uchio EM; Department of Urology, University of California Irvine, Irvine, CA, USA., Jung SI; Department of Urology, Chonnam National University Hwasun Hospital, Jeollanam-do, South Korea., Bivalacqua TJ; Department of Urology, University of Pennsylvania, Philadelphia, PA, USA., Steinberg GD; Department of Urology, Rush University Medical Center, Chicago, IL, USA., Shore ND; START Carolinas/Carolina Urologic Research Center, Myrtle Beach, SC, USA., Burke JM; Cody Regional Health Big Horn Basin Cancer Center, Cody, WY, USA., Kitamura H; Department of Urology, University of Toyama, Toyama, Japan., Tran B; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Li R; Department of Genitourinary Oncology, H Lee Moffitt Cancer Center, Tampa, FL, USA.

Πηγή: The Lancet. Oncology [Lancet Oncol] 2026 Aug; Vol. 27 (8), pp. 983-993.

Τύπος έκδοσης: Journal Article; Clinical Trial, Phase III; Multicenter Study

Στοιχεία περιοδικού: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Non-Muscle Invasive Bladder Neoplasms*/therapy , Non-Muscle Invasive Bladder Neoplasms*/pathology , Oncolytic Virotherapy*/adverse effects , Oncolytic Virotherapy*/methods , Carcinoma in Situ*/pathology , Carcinoma in Situ*/therapy , Carcinoma in Situ*/drug therapy , Carcinoma in Situ*/immunology , Urinary Bladder Neoplasms*/pathology, BCG Vaccine/administration & dosage ; BCG Vaccine/therapeutic use ; Humans ; Female ; Male ; Aged ; Administration, Intravesical ; Middle Aged ; Treatment Outcome

Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors.

Συγγραφείς: Merchan JR; University of Miami, Miami, Florida., Patel MR; University of Minnesota , Minneapolis, Minnesota., Cripe TP; Nationwide Children's Hospital , Columbus, Ohio., Old MO; Ohio State University, Columbus, Ohio., Boughton J; Vyriad, Rochester, Minnesota., Diaz RM; Vyriad, Rochester, Minnesota., Peng KW; Vyriad, Rochester, Minnesota.; Mayo Clinic , Rochester, Minnesota., Russell SJ; Vyriad, Rochester, Minnesota.; Mayo Clinic , Rochester, Minnesota., Russell L; Vyriad, Rochester, Minnesota., Packiriswamy N; Vyriad, Rochester, Minnesota., Wiegert E; Bexon Clinical Consulting LLC, Montclair, New Jersey., Bexon AS; Bexon Clinical Consulting LLC, Montclair, New Jersey., Powell SF; Sanford Health, Sioux Falls, South Dakota.

Πηγή: Cancer research communications [Cancer Res Commun] 2026 Aug 01; Vol. 6 (8), pp. 1862-1874.

Τύπος έκδοσης: Journal Article; Clinical Trial, Phase I; Multicenter Study

Στοιχεία περιοδικού: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9918281580506676 Publication Model: Print Cited Medium: Internet ISSN: 2767-9764 (Electronic) Linking ISSN: 27679764 NLM ISO Abbreviation: Cancer Res Commun Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/adverse effects , Neoplasms*/therapy , Neoplasms*/pathology , Neoplasms*/immunology , Oncolytic Viruses*/genetics , Oncolytic Virotherapy*/methods , Oncolytic Virotherapy*/adverse effects , Neoplasm Recurrence, Local*/therapy , Antineoplastic Agents, Immunological*/therapeutic use, Humans ; Female ; Male ; Middle Aged ; Aged ; Adult ; Combined Modality Therapy

Matrix metalloproteinase-guided targeting of vesicular stomatitis virus to tumors following systemic administration.

Συγγραφείς: Theune EV; Department of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA., Theune WC; Department of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA., Ahmadi E; Department of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA., Chiari CC; Department of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA., Singh N; Department of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA., Geyer R; Department of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA., Tonne J; Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA., Metko M; Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA., Olaoba OT; Department of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA.; Department of Surgery, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA., Wang IC; Department of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA.; Johns Hopkins University, Baltimore, MD, USA., Dai D; Department of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA.; University of Connecticut, Storrs, CT, USA., Ruan J; Department of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA., Clark R; Department of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA., Li G; Department of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA.; Department of Surgery, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA., Wang P; Department of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA., Jellison ER; Department of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA., Vella AT; Department of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA., Vile R; Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.; Department of Immunology, Mayo Clinic, Rochester, MN, USA.; Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, School of Immunology and Microbial Sciences, King's College London, London, UK., Wang K; Department of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA. kewang@uchc.edu.

Πηγή: Signal transduction and targeted therapy [Signal Transduct Target Ther] 2026 Oct 20; Vol. 11 (1). Date of Electronic Publication: 2026 Oct 20.

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101676423 Publication Model: Electronic Cited Medium: Internet ISSN: 2059-3635 (Electronic) Linking ISSN: 20593635 NLM ISO Abbreviation: Signal Transduct Target Ther Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Interleukin-12*/genetics , Vesiculovirus*/genetics , Matrix Metalloproteinases*/genetics , Viral Envelope Proteins*/genetics , Oncolytic Virotherapy*, Tumor Microenvironment/immunology ; Tumor Microenvironment/genetics ; Oncolytic Viruses/genetics ; Vesicular stomatitis Indiana virus/genetics ; Animals ; Mice ; Humans ; Membrane Glycoproteins

Oncolytic virus encoding decorin and the CD40 ligand boosts T-cell response and achieves a durable antitumor response during breast cancer treatment.

Συγγραφείς: Ning Y; Centre for Medical Research, Ningbo No.2 Hospital, Ningbo, 315010, China., Rong Y; Centre for Medical Research, Ningbo No.2 Hospital, Ningbo, 315010, China., Meng H; The First Affiliated Hospital of Ningbo University, Ningbo, 315010, China., Lin Y; Centre for Medical Research, Ningbo No.2 Hospital, Ningbo, 315010, China., Chen W; Centre for Medical Research, Ningbo No.2 Hospital, Ningbo, 315010, China., Shi Q; Centre for Medical Research, Ningbo No.2 Hospital, Ningbo, 315010, China., Zhang S; Centre for Medical Research, Ningbo No.2 Hospital, Ningbo, 315010, China., Li H; Centre for Medical Research, Ningbo No.2 Hospital, Ningbo, 315010, China. lihongshan_1982@126.com., Yang Y; Centre for Medical Research, Ningbo No.2 Hospital, Ningbo, 315010, China. yuefengyang1981@163.com.; Beijing Jingda Biotechnology Co. Ltd, Beijing, 102629, China. yuefengyang1981@163.com.

Πηγή: Molecular biomedicine [Mol Biomed] 2026 Oct 05; Vol. 7 (1). Date of Electronic Publication: 2026 Oct 05.

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: Springer Singapore Country of Publication: Singapore NLM ID: 9918283581406676 Publication Model: Electronic Cited Medium: Internet ISSN: 2662-8651 (Electronic) Linking ISSN: 26628651 NLM ISO Abbreviation: Mol Biomed Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Decorin*/genetics , Decorin*/metabolism , CD40 Ligand*/genetics , CD40 Ligand*/metabolism , Oncolytic Viruses*/genetics , Triple Negative Breast Neoplasms*/therapy , Triple Negative Breast Neoplasms*/immunology , Triple Negative Breast Neoplasms*/pathology , T-Lymphocytes*/immunology , Oncolytic Virotherapy*, Adenoviridae/genetics ; Dendritic Cells/immunology ; Animals ; Female ; Humans ; Cell Line, Tumor ; Mice ; Apoptosis ; Mice, Inbred BALB C

Oncolytic Herpes Virus G47Δ Potentiates ADCC-Inducing Molecular Targeted Therapy via Coordinated Activation of Innate and Adaptive Immune Responses.

Συγγραφείς: Nagatomo T; Division of Innovative Cancer Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.; Department of Otolaryngology-Head and Neck Surgery, Jichi Medical University, Tochigi-ken, Japan., Iwai M; Division of Innovative Cancer Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Tanaka M; Division of Innovative Cancer Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Nishino H; Department of Otolaryngology-Head and Neck Surgery, Jichi Medical University, Tochigi-ken, Japan., Todo T; Division of Innovative Cancer Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Πηγή: Molecular cancer therapeutics [Mol Cancer Ther] 2026 Oct 02; Vol. 25 (10), pp. 1691-1701.

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Oncolytic Virotherapy*/methods , Oncolytic Viruses*/genetics , Oncolytic Viruses*/immunology , Antibody-Dependent Cell Cytotoxicity*/immunology , Antibody-Dependent Cell Cytotoxicity*/drug effects , Immunity, Innate* , Adaptive Immunity*, Cetuximab/pharmacology ; ErbB Receptors/antagonists & inhibitors ; Dendritic Cells/immunology ; Killer Cells, Natural/immunology ; Animals ; Humans ; Mice ; Cell Line, Tumor ; Molecular Targeted Therapy ; Female ; Disease Models, Animal

Oncolytic Vaccinia Virus Armed With CLEC2A Enhances Antitumor Immunity via ROS-Autophagy Feedback Loop and Cytokine Activation.

Συγγραφείς: Su J; Zhejiang Provincial Engineering Research Center of New Technologies and Applications for Targeted Therapy of Major Diseases, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China., Zhai C; Zhejiang Provincial Engineering Research Center of New Technologies and Applications for Targeted Therapy of Major Diseases, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China., Li Y; Zhejiang Provincial Engineering Research Center of New Technologies and Applications for Targeted Therapy of Major Diseases, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China., Liu R; Zhejiang Provincial Engineering Research Center of New Technologies and Applications for Targeted Therapy of Major Diseases, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China., Zhu J; Zhejiang Provincial Engineering Research Center of New Technologies and Applications for Targeted Therapy of Major Diseases, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China., Chen K; Zhejiang Provincial Engineering Research Center of New Technologies and Applications for Targeted Therapy of Major Diseases, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China., Zhou Y; Zhejiang Provincial Engineering Research Center of New Technologies and Applications for Targeted Therapy of Major Diseases, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China., Ye T; Zhejiang Provincial Engineering Research Center of New Technologies and Applications for Targeted Therapy of Major Diseases, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China., Li G; Zhejiang Provincial Engineering Research Center of New Technologies and Applications for Targeted Therapy of Major Diseases, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China.

Πηγή: Journal of medical virology [J Med Virol] 2026 Oct; Vol. 98 (10), pp. e71174.

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print Cited Medium: Internet ISSN: 1096-9071 (Electronic) Linking ISSN: 01466615 NLM ISO Abbreviation: J Med Virol Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Vaccinia virus*/genetics , Vaccinia virus*/immunology , Reactive Oxygen Species*/metabolism , Cytokines*/metabolism , Lectins, C-Type*/genetics , Lectins, C-Type*/metabolism , Lectins, C-Type*/immunology , Oncolytic Viruses*/genetics , Oncolytic Viruses*/immunology , Oncolytic Virotherapy*/methods , Autophagy*, CD8-Positive T-Lymphocytes/immunology ; Melanoma/therapy ; Killer Cells, Natural/immunology ; Animals ; Humans ; Mice ; Female ; Cell Line, Tumor ; Mice, Inbred C57BL ; Disease Models, Animal

Oncolytic virus-delivered CEACAM6/CD3 BiTEs combine with PD-1 blockade to achieve synergistic anticancer efficacy.

Συγγραφείς: Zhang W; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, China; Department of Oncology, Cancer Prevention and Treatment Institute of Chengdu, Chengdu Fifth People's Hospital (The Second Clinical Medical College, Affiliated Fifth People's Hospital of Chengdu University of Traditional Chinese Medicine), Chengdu, Sichuan Province 610041, China., Dai S; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, China., Fan H; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, China., Yang N; State Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, China., Xu L; State Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, China., Liu Z; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, China., Min Y; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, China., Jiang Z; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, China., Zhou L; Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, China; Department of Neurosurgery, NHC Key Laboratory of Nuclear Technology Medical Transformation（Mianyang Central Hospital), School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan Province 621000, China., Yang H; Department of Otolaryngology-Head & Neck Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, China., Tong A; State Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, China; Frontiers Medical Center, Tianfu Jincheng Laboratory, Chengdu, Sichuan Province 610212, China. Electronic address: aipingtong@scu.edu.cn., Peng X; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, China; Nuclear Physics and Medical Research Key Laboratory of Sichuan Province, Sichuan University, Chengdu, Sichuan Province 610041, China. Electronic address: pxx2014@163.com.

Πηγή: Pharmacological research [Pharmacol Res] 2026 Oct; Vol. 232, pp. 108392. Date of Electronic Publication: 2026 Aug 13.

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8907422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-1186 (Electronic) Linking ISSN: 10436618 NLM ISO Abbreviation: Pharmacol Res Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Oncolytic Virotherapy*/methods , Oncolytic Viruses*/genetics , CD3 Complex*/immunology , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Programmed Cell Death 1 Receptor*/immunology , Carcinoembryonic Antigen*/immunology , Immune Checkpoint Inhibitors*/therapeutic use , Immune Checkpoint Inhibitors*/pharmacology , Colonic Neoplasms*/therapy , Colonic Neoplasms*/immunology , Cell Adhesion Molecules*/immunology , Antibodies, Bispecific*, GPI-Linked Proteins/immunology ; GPI-Linked Proteins/antagonists & inhibitors ; T-Lymphocytes/immunology ; Simplexvirus/genetics ; Animals ; Female ; Humans ; Cell Line, Tumor ; Mice ; Mice, Inbred BALB C ; Tumor Microenvironment ; Antigens, CD